• Targeted mRNA Nanoparticles Restore BBB Post-Stroke via Micr

  2026-07-16

  A recent study demonstrates that M2 microglia-targeting lipid nanoparticles (MLNPs) delivering interleukin-10 mRNA can significantly ameliorate blood–brain barrier (BBB) disruption following ischemic stroke by promoting reparative microglial phenotypes. This approach offers a promising, time-extended strategy for poststroke neurological protection and could reshape mRNA therapeutic delivery for central nervous system disorders.

• AhR Antagonism Mitigates MEHP-Induced Ovarian Toxicity in Mi

  2026-07-16

  This study reveals that the aryl hydrocarbon receptor (AhR) mediates the ovarian toxicity of mono(2-ethylhexyl) phthalate (MEHP), a key phthalate metabolite, impairing follicle growth and estrogen production in mouse antral follicles. Importantly, the use of the AhR antagonist CH 223191 partially rescues these effects, highlighting AhR as a mechanistic target for environmental toxicology and reproductive research.

• (R)-MG132: Unmatched Negative Control in Proteasome Research

  2026-07-15

  (R)-MG132, the functionally inactive MG-132 enantiomer, is the gold-standard negative control for validating proteasome-dependent mechanisms in cell-based assays. By discriminating true on-target effects from off-target artifacts, it enables rigorous and reproducible ubiquitin-proteasome system research.

• Phosbind Acrylamide: Advancing Translational Phosphoproteomi

  2026-07-15

  Explore how Phos binding reagent (Phosbind) acrylamide empowers translational researchers to dissect phosphorylation-driven signaling, with strategic insight into workflow optimization, reference to the latest plant signaling breakthroughs, and a critical look at the competitive landscape.

• (-)-JQ1: Benchmark Stereoisomer Negative Control in Epigenet

  2026-07-14

  (-)-JQ1 is a rigorously validated JQ1 stereoisomer widely used as a negative control in BET bromodomain inhibition research. It provides essential assay specificity in epigenetics and cancer biology studies, supporting the accurate interpretation of BRD4-dependent effects.

• AIBP-LRP2–HDL Axis Regulates CXCR4+ Capillary Expansion in I

  2026-07-14

  This study elucidates a two-phase mechanism by which AIBP-LRP2–mediated HDL uptake limits the expansion of CXCR4+ stemlike capillary endothelial cells and thus restricts collateral circulation in ischemic vascular disease. These insights reveal new molecular targets for therapeutic modulation of vascular remodeling and revascularization.

• ATRX Loss Sensitizes High-Grade Glioma to RTK/PDGFR Inhibiti

  2026-07-13

  This article discusses recent evidence that ATRX-deficient high-grade glioma cells display heightened sensitivity to receptor tyrosine kinase (RTK) and PDGFR inhibitors. These findings suggest a potential precision-medicine approach for glioma patients and highlight the need to consider ATRX status in clinical trial stratification and therapeutic strategy.

• EZ Cap™ Cas9 mRNA (m1Ψ): Leveraging mRNA Engineering for Saf

  2026-07-13

  Explore how EZ Cap™ Cas9 mRNA (m1Ψ) redefines genome editing precision and safety through advanced mRNA engineering, including Cap1 structure and m1Ψ modification. This article examines nuclear export regulation and immune evasion, offering unique scientific insights for researchers seeking next-generation CRISPR-Cas9 solutions.

• (+)-Bicuculline: Technical Guidance for GABAA Antagonist Wor

  2026-07-12

  (+)-Bicuculline is a competitive GABAA receptor antagonist widely used in neuroscience research to interrogate inhibitory neurotransmission and modulate synaptic NMDA receptor signaling. It is not suitable for diagnostic or clinical use and requires strict adherence to solubility and storage protocols for reliable results.

• Spermine Tetrahydrochloride: Precision Control in Protoplast

  2026-07-10

  Explore the science of spermine tetrahydrochloride in membrane protection, protein crystallization, and advanced crosslinking, revealing evidence-driven assay design and practical insights not found in prior content.

• (-)-JQ1: Precision Control for BET Bromodomain Assays

  2026-07-09

  (-)-JQ1 offers researchers the gold-standard negative control for dissecting BET bromodomain function in epigenetics and cancer biology workflows. Its rigorous application ensures confident differentiation of on-target effects from off-target noise, directly supporting reproducibility and precision in BRD4-targeted studies.

• KPT330 Enhances CRISPR-Cas9 Specificity via mRNA Nuclear Exp

  2026-07-09

  The referenced study demonstrates that the FDA-approved drug KPT330, a selective inhibitor of nuclear export (SINE), can improve the precision of CRISPR-Cas9 genome and base editing by regulating Cas9 mRNA nuclear export. This discovery introduces a new, indirect approach to reducing off-target effects in genome engineering, offering practical avenues for safer and more accurate gene editing.

• Dietary Arachidonic Acid Enhances Vaccine-Induced Humoral Im

  2026-07-08

  A recent study demonstrates that dietary supplementation with arachidonic acid significantly accelerates and amplifies vaccine-induced neutralizing antibody production in both mice and humans. This mechanistic insight reveals arachidonic acid's role as a modulator of germinal center B cell responses, with implications for rapid immunization strategies.

• Refining In Vitro Drug Response Evaluation in Cancer Researc

  2026-07-08

  Schwartz's dissertation advances the methodology for evaluating anti-cancer drug responses in vitro by distinguishing between proliferative arrest and cell death. These insights clarify how DNA methyltransferase inhibitors like SGI-1027 can be more accurately assessed for their dual effects, improving experimental reproducibility and translational relevance.

• Dual-Genome OXPHOS Disruption: LRPPRC Inhibition Plus Dasati

  2026-07-07

  The reference study reveals a novel strategy for cancer therapy by combining LRPPRC inhibition with Dasatinib, resulting in synergistic disruption of mitochondrial oxidative phosphorylation (OXPHOS) through coordinated nuclear and mitochondrial gene suppression. These findings offer mechanistic insights and a rationale for combination therapies in OXPHOS-dependent tumors.

546 records 11/37 page Previous Next First page 上5页 1112131415 下5页 Last page